The Supreme Court is set to hear oral arguments on Tuesday, March 26, in a case that could have a significant impact on how mifepristone — the first drug used in a two-drug medication abortion regimen — is used and prescribed in the United States.
The case, FDA v. Alliance for Hippocratic Medicine, surrounds the U.S. Food and Drug Administration’s (FDA) rolling back of safety restrictions for mifepristone, including its 2016 action extending the permissible gestational age of the baby for which a girl or woman may take abortion drugs from seven weeks gestation to ten weeks gestation and its 2021 rule change allowing abortionists to send mifepristone through the mail. The FDA also recently made permanent its rule to allow women and girls to receive a prescription for mifepristone via telemedicine.
The Alliance Defending Freedom (ADF) filed the lawsuit in November of…
